2025 San Francisco - Bay Area Patient and Family Conference
Event Date:
Sat, 07/19/2025 - 10:30am (EDT)
Bone Marrow Disease(s):
Conference Event Type:
treatment
Secondary AML - Webinar 2025
In this webinar, Drs. Fadi Haddad and Jayastu Senapati discuss the diagnosis secondary AML from MDS, treatment options available to patients and symptom management.
AAMDSIF Supports the Accelerating Kids' Access to Care Act
AAMDSIF Supports the Accelerating Kids' Access to Care Act.
On March 26, 2025, AAMDSIF joined with 212 additional patient advocacy and medical center organizations in urging members of the US Congress to pass the Accelerating Kids’ Access to Care Act.
Passage of this bill will permit faster, more thorough care, for children with complex medical conditions.
Please view the PDF below.
Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the
ABSTRACT
How Our Lungs Back Up the Bone Marrow to Make Our Blood
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes
Abstract
How I treat secondary acute myeloid leukemia
Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) is Associated With Better Overall Survival
Section snippets
Background
How I use maintenance therapy in acute myeloid leukemia
Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia
Dear Editor,